Roche and Medivir begin hepatitis C research

Swiss pharmaceuticals companies Roche Holding AG and Medivir AB are to amend their existing HIV collaboration and begin a joint research program into hepatitis C, it was announced in a joint press release.

Medivir assumes full responsibility for the MV026048 compound being tested against HIV, with Roche continuing to participate in a guidance capacity.